LF3
Based on 14 publication(s) in Google Scholar
LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM.
For research use only. We do not sell to patients.
- Purity: 99.55%
- CAS No.: 664969-54-4
- Formula: C20H24N4O2S2
- Molecular Weight:416.56
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Cytoskeleton Compound Library
HY-L060
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Antihypertensive Compound Library
HY-L145
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Peptidomimetic Library
HY-L033
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) LF3
More- Mil Med Res. 2022 Sep 27;9(1):54. [Abstract]
- Adv Sci (Weinh). 2025 Apr;12(14):e2413445. [Abstract]
- Sci Adv. 2022 Dec 9;8(49):eabq8596. [Abstract]
- Cell Death Differ. 2024 Nov;31(11):1452-1466. [Abstract]
- J Neuroinflammation. 2025 Mar 18;22(1):87. [Abstract]
- J Mol Cell Biol. 2025 Dec 5:mjaf050. [Abstract]
- J Mol Cell Biol. 2025 Jul 28;17(2):mjaf002. [Abstract]
- Mol Cancer Res. 2022 Jun 3;20(6):949-959. [Abstract]
- Int Immunopharmacol. 2025 Sep 23:162:115181. [Abstract]
- Comput Struct Biotechnol J. 2023 Jan 16:21:956-964. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2026 Mar 9. [Abstract]
- Cell Cycle. 2024 Feb;23(4):435-447. [Abstract]
- Biochem Biophys Res Commun. 2024 Nov 19:734:150460. [Abstract]
- Biochem Biophys Res Commun. 2019 Aug 27;516(3):819-824. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Flow Cytometry
-
WB
-
RT-PCR
Biological Activity
IC50: 1.65 μM (β-Catenin/TCF4, AlphaScreen), 1.82 μM (β-Catenin/TCF4, ELISA)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DLD-1 | IC50 |
18 nM
Compound: 134; LF3
|
Anticancer activity against human DLD-1 cells assessed as reduction in cell viability
Anticancer activity against human DLD-1 cells assessed as reduction in cell viability
|
[PMID: 33445154] |
LF3 inhibits Wnt/β-catenin signals in cells with exogenous reporters and in colon cancer cells with endogenously high Wnt activity. LF3 also suppresses features of cancer cells related to Wnt signaling, including high cell motility, cell-cycle progression, and the overexpression of Wnt target genes. However, LF3 does not cause cell death or interfere with cadherin-mediated cell-cell adhesion. Remarkably, the self-renewal capacity of cancer stem cells is blocked by LF3 in concentration-dependent manners[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 664969-54-4
-
Appearance Solid
-
Molecular Weight 416.56
-
Formula C20H24N4O2S2
-
Color White to off-white
-
SMILES
S=C(N1CCN(C/C=C/C2=CC=CC=C2)CC1)NC3=CC=C(S(=O)(N)=O)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Mil Med Res
Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability. [Abstract]2022 Sep 27;9(1):54. PMID: 36163081 -
Adv Sci (Weinh)
Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer. [Abstract]2025 Apr;12(14):e2413445. PMID: 39887933 -
Sci Adv
2022 Dec 9;8(49):eabq8596. PMID: 36490351 -
Cell Death Differ
2024 Nov;31(11):1452-1466. PMID: 38987382
LF3 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2024 Nov;31(11):1452-1466. [Abstract]
CAL27 cells following treatment with ES-Cu (100 nM) and LF3 (10 μM) in the absence or presence of TTM (40 μM), Z-VAD-FMK (20 μM), Nec-1 (20 μM), or Fer-1 (10 μM) for 24 h.
LF3 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2024 Nov;31(11):1452-1466. [Abstract]
Growth curves of B16-F10 tumor treated with LF3 (50 mg/kg, i.p.) in combination with ES-Cu.
LF3 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2024 Nov;31(11):1452-1466. [Abstract]
Mitochondrial ROS levels of CAL27 and FaDu sphere cells treated with ES-Cu (100 nM) for 24 h.
LF3 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2024 Nov;31(11):1452-1466. [Abstract]
WB analysis of the indicated markers in CAL27 cells followed by TCF4-coding plasmid and LF3 treatment (10 μM) for 24 h.
LF3 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2024 Nov;31(11):1452-1466. [Abstract]
Q-PCR and analysis of the indicated markers in CAL27 and A375 sphere cells followed by TCF4-coding plasmid and LF3 treatment (CAL27 sphere, 10 μM; A375 sphere, 5 μM) for 24 h.
-
J Neuroinflammation
Inhibition of neutrophil extracellular traps alleviates blood-brain barrier disruption and cognitive dysfunction via Wnt3/β-catenin/TCF4 signaling in sepsis-associated encephalopathy. [Abstract]2025 Mar 18;22(1):87. PMID: 40102948 -
J Mol Cell Biol
Canonical Wnt signaling affects calcium homeostasis in serum-treated AC16 cells through MLN-mediated SERCA2a regulation. [Abstract]2025 Dec 5:mjaf050. PMID: 41348974 -
J Mol Cell Biol
Wnt/β-catenin pathway induces cardiac dysfunction via AKAP6-mediated RyR2 phosphorylation and sarcoplasmic reticulum calcium leakage. [Abstract]2025 Jul 28;17(2):mjaf002. PMID: 40097291 -
Mol Cancer Res
Constitutive β-Catenin Overexpression Represses Lncrna MIR100HG Transcription via HDAC6-Mediated Histone Modification in Colorectal Cancer. [Abstract]2022 Jun 3;20(6):949-959. PMID: 35247921 -
Int Immunopharmacol
YTHDF1-mediated mitochondrial dysfunction and allergic airway inflammation by interaction with β-catenin/TCF4 signaling. [Abstract]2025 Sep 23:162:115181. PMID: 40633209 -
Comput Struct Biotechnol J
A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer. [Abstract]2023 Jan 16:21:956-964. PMID: 36733702 -
Naunyn Schmiedebergs Arch Pharmacol
Small-molecule LF3 alleviates angiotensin II-induced cardiac dysfunction via attenuating cardiac fibrosis. [Abstract]2026 Mar 9. PMID: 41796236 -
Cell Cycle
SIRT3 suppression resulting from the enhanced β-catenin signaling drives glycolysis and promotes hypoxia-induced cell growth in hepatocellular carcinoma cells. [Abstract]2024 Feb;23(4):435-447. PMID: 38626328 -
Biochem Biophys Res Commun
Dihydroquercetin improves the proliferation of porcine intestinal epithelial cells via the Wnt/β-catenin pathway. [Abstract]2024 Nov 19:734:150460. PMID: 39083968 -
Biochem Biophys Res Commun
2019 Aug 27;516(3):819-824. PMID: 31262447
Solvent & Solubility
DMSO : 233.33 mg/mL (560.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (12.00 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
LF3 is dissolved in DMSO to a concentration of 50 mM and diluted with culture medium. Two colon cancer cell lines (HCT116 and HT29) and a breast cancer cell line (MCF7) are treated with LF3 (0, 30, 60 μM) for 24 hours and labeled with BrdUrd for 4 to 5 hours to detect proliferating cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: Unsorted GFPlow and GFPhigh SW480 cells are subcutaneously injected into the back skin of NOD/SCID mice. Tumor growth is monitored over a period of 45 days. For therapy, LF3 is administered i.v. at 50 mg/kg body weight for three rounds over 5 consecutive days, with 2-day breaks[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4006 mL | 12.0031 mL | 24.0061 mL | 60.0154 mL |
| 5 mM | 0.4801 mL | 2.4006 mL | 4.8012 mL | 12.0031 mL | |
| 10 mM | 0.2401 mL | 1.2003 mL | 2.4006 mL | 6.0015 mL | |
| 15 mM | 0.1600 mL | 0.8002 mL | 1.6004 mL | 4.0010 mL | |
| 20 mM | 0.1200 mL | 0.6002 mL | 1.2003 mL | 3.0008 mL | |
| 25 mM | 0.0960 mL | 0.4801 mL | 0.9602 mL | 2.4006 mL | |
| 30 mM | 0.0800 mL | 0.4001 mL | 0.8002 mL | 2.0005 mL | |
| 40 mM | 0.0600 mL | 0.3001 mL | 0.6002 mL | 1.5004 mL | |
| 50 mM | 0.0480 mL | 0.2401 mL | 0.4801 mL | 1.2003 mL | |
| 60 mM | 0.0400 mL | 0.2001 mL | 0.4001 mL | 1.0003 mL | |
| 80 mM | 0.0300 mL | 0.1500 mL | 0.3001 mL | 0.7502 mL | |
| 100 mM | 0.0240 mL | 0.1200 mL | 0.2401 mL | 0.6002 mL |
LF3 Related Classifications
HY-101486 Related Classifications
Powered by Bioz